Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almer, G.
Right arrow Articles by Przedborski, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almer, G.
Right arrow Articles by Przedborski, S.
Related Collections
Right arrow All Immunology
Right arrow Anterior nerve cell disease
Right arrow Amyotrophic lateral sclerosis
Neurology 2002;58:1277-1279
© 2002 American Academy of Neurology
Brief Communications

Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients

G. Almer, MD, P. Teismann, PhD, Z. Stevic, MD, J. Halaschek–Wiener, MS, L. Deecke, MD, V. Kostic, MD PhD and S. Przedborski, MD PhD

From the Universitätsklinik für Neurologie (Drs. Almer and Deecke), Allgemeines Krankenhaus der Stadt Wien, and the Department of Clinical Pharmacology (J. Halaschek–Wiener), University of Vienna, Austria; Departments of Neurology (Drs. Almer, Teismann, and Przedborski) and Pathology (Dr. Przedborski), Columbia University, New York, NY; and Institute of Neurology (Drs. Stevic and Kostic), Clinical Center of Serbia, Belgrade, Yugoslavia.

Address correspondence and reprint requests to Dr. Serge Przedborski, Departments of Neurology and Pathology, BB-307, Columbia University, 650 West 168th Street, New York, NY 10032; e-mail: SP30{at}Columbia.edu

Levels of the potent pro-inflammatory prostaglandin E2 (PGE2) are elevated in postmortem spinal cords from patients with ALS, and inhibition of a key PGE2-synthesizing enzyme, cylcooxygenase-2, is neuroprotective in an in vitro model of ALS. The authors report that 82% of the patients with ALS studied had 2 to 10 times higher PGE2 levels in CSF compared with normal control subjects. That affected areas of the CNS are inflamed in ALS supports this. CSF PGE2 measurement may be useful in monitoring treatment for ALS.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Combrinck, J Williams, M A De Berardinis, D Warden, M Puopolo, A D Smith, and L Minghetti
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 85 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P J Shaw
Molecular and cellular pathways of neurodegeneration in motor neurone disease
J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1046 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Devos, C. Moreau, P. Lassalle, T. Perez, J. De Seze, V. Brunaud-Danel, A. Destee, A. B. Tonnel, and N. Just
Low levels of the vascular endothelial growth factor in CSF from early ALS patients
Neurology, June 8, 2004; 62(11): 2127 - 2129.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.